BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · Real-Time Price · USD
7.69
+0.06 (0.79%)
At close: Nov 6, 2026, 4:00 PM EST
7.71
+0.02 (0.26%)
After-hours: Nov 6, 2026, 7:30 PM EST
BioCryst Pharmaceuticals Revenue
BioCryst Pharmaceuticals had revenue of $180.29M in the quarter ending September 30, 2026, with 13.11% growth. This brings the company's total for the last twelve months to $961.51M, up 60.30% year-over-year. In the year 2025, BioCryst Pharmaceuticals had annual revenue of $874.84M with 94.10% growth. That makes BioCryst Pharmaceuticals the 7,807th largest company in the world by revenue and 1,823rd in the United States.
Revenue (ttm)
$961.51M
Revenue Growth
+60.30%
P/S Ratio
2.06
Revenue / Employee
$2,210,368
Employees
435
Market Cap
1.98B
Revenue by Geography
- United States 548.78M 62.7%
- Unallocated 273.00M 31.2%
- Outside United States 53.06M 6.1%
Fiscal year ended Dec 31, 2025 See the full BioCryst Pharmaceuticals breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 874.84M | 424.13M | 94.10% |
| Dec 31, 2024 | 450.71M | 119.30M | 36.00% |
| Dec 31, 2023 | 331.41M | 60.59M | 22.37% |
| Dec 31, 2022 | 270.83M | 113.66M | 72.31% |
| Dec 31, 2021 | 157.17M | 139.36M | 782.38% |
| Dec 31, 2020 | 17.81M | -31.02M | -63.53% |
| Dec 31, 2019 | 48.84M | 28.18M | 136.45% |
| Dec 31, 2018 | 20.65M | -4.53M | -18.00% |
| Dec 31, 2017 | 25.19M | -1.17M | -4.43% |
| Dec 31, 2016 | 26.35M | -21.90M | -45.39% |
| Dec 31, 2015 | 48.26M | 34.65M | 254.62% |
| Dec 31, 2014 | 13.61M | -3.72M | -21.48% |
| Dec 31, 2013 | 17.33M | -8.96M | -34.09% |
| Dec 31, 2012 | 26.29M | 6.65M | 33.85% |
| Dec 31, 2011 | 19.64M | -42.74M | -68.51% |
| Dec 31, 2010 | 62.38M | -12.21M | -16.37% |
| Dec 31, 2009 | 74.59M | 18.03M | 31.87% |
| Dec 31, 2008 | 56.56M | -14.68M | -20.60% |
| Dec 31, 2007 | 71.24M | 65.03M | 1,046.79% |
| Dec 31, 2006 | 6.21M | 6.06M | 3,990.38% |
| Dec 31, 2005 | 151.87K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Perrigo Company | 4.09B |
| Phibro Animal Health | 1.54B |
| Prestige Consumer Healthcare | 1.17B |
| Trulieve Cannabis | 1.08B |
| ANI Pharmaceuticals | 1.04B |
| Pacira BioSciences | 743.30M |
| HUTCHMED (China) | 549.12M |
| Alvotech | 494.61M |
BCRX News
- 3 days ago - BioCryst to Present at Upcoming Investor Conferences - GlobeNewsWire
- 3 days ago - BioCryst Pharmaceuticals Earnings Call Transcript: Q3 2026 - Transcripts
- 3 days ago - BioCryst Pharmaceuticals Earnings release: Q3 2026 - Filings
- 3 days ago - BioCryst Pharmaceuticals Slides: Q3 2026 - Filings
- 3 days ago - BioCryst Pharmaceuticals Quarterly report: Q3 2026 - Filings
- 3 days ago - BioCryst Reports Third Quarter 2026 Financial Results - GlobeNewsWire
- 9 days ago - BioCryst to Present New Data for ORLADEYO® (berotralstat) and Navenibart at the 2026 American College of Allergy, Asthma & Immunology Annual Scientific Meeting - GlobeNewsWire
- 17 days ago - BioCryst to Report Third Quarter 2026 Financial Results on November 4 - GlobeNewsWire